Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
NIH-logos NIGMS Logo NIAAA Logo NCI Logo NIH Logo
Curated Information Page
PubMed Id: 17621270 
This page summarizes selected information from the article referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2012,40:D261-70). To learn more about the scope of PhosphoSitePlus®, click here.
Preet A, Ganju RK, Groopman JE (2008) Delta9-Tetrahydrocannabinol inhibits epithelial growth factor-induced lung cancer cell migration in vitro as well as its growth and metastasis in vivo. Oncogene 27, 339-46 17621270
Only sites from this record are displayed on this page. Click on the protein name to open the protein page, and on the RSD number to open the site page. For the complete dataset, click the download button, on the right.
Download Sites

S473-p - Akt1 (human) ▲
Orthologous residues
Akt1 (human): S473‑p, Akt1 (mouse): S473‑p, Akt1 (rat): S473‑p, Akt1 (fruit fly): S586‑p, Akt1 (cow): S473‑p
Characterization
 Methods used to characterize site in vivo:  phospho-antibody, western blotting
 Disease tissue studied:  lung cancer
 Relevant cell lines - cell types - tissues:  A549 (pulmonary)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
EGF increase
THC no change compared to control
THC EGF inhibit treatment-induced increase
EGF increase
THC no change compared to control
THC EGF inhibit treatment-induced increase
THC decrease
Associated Diseases
Diseases: Alterations: Comments:
non-small cell lung cancer

Y1172-p - EGFR (human) ▲
Orthologous residues
EGFR (human): Y1172‑p, EGFR (mouse): Y1172‑p, EGFR (rat): Y1171‑p, EGFR (pig): Y1171‑p
Characterization
 Methods used to characterize site in vivo:  phospho-antibody, western blotting
 Disease tissue studied:  lung cancer
 Relevant cell lines - cell types - tissues:  A549 (pulmonary)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
EGF increase
THC EGF no effect upon treatment-induced increase
THC no change compared to control
Associated Diseases
Diseases: Alterations: Comments:
non-small cell lung cancer

T202-p - ERK1 (human) ▲
Orthologous residues
ERK1 (human): T202‑p, ERK1 (mouse): T203‑p, ERK1 (rat): T203‑p, ERK1 (hamster): T192‑p
Characterization
 Methods used to characterize site in vivo:  phospho-antibody, western blotting
 Disease tissue studied:  lung cancer
 Relevant cell lines - cell types - tissues:  A549 (pulmonary)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
EGF increase
THC decrease
THC EGF inhibit treatment-induced increase
EGF increase
THC no change compared to control
THC EGF no effect upon treatment-induced increase
THC decrease
Associated Diseases
Diseases: Alterations: Comments:
non-small cell lung cancer

Y204-p - ERK1 (human) ▲
Orthologous residues
ERK1 (human): Y204‑p, ERK1 (mouse): Y205‑p, ERK1 (rat): Y205‑p, ERK1 (hamster): Y194‑p
Characterization
 Methods used to characterize site in vivo:  phospho-antibody, western blotting
 Disease tissue studied:  lung cancer
 Relevant cell lines - cell types - tissues:  A549 (pulmonary)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
THC decrease
EGF increase
THC no change compared to control
THC EGF no effect upon treatment-induced increase
EGF increase
THC decrease
THC EGF inhibit treatment-induced increase
Associated Diseases
Diseases: Alterations: Comments:
non-small cell lung cancer

T185-p - ERK2 (human) ▲
Orthologous residues
ERK2 (human): T185‑p, ERK2 (mouse): T183‑p, ERK2 (rat): T183‑p, ERK2 (chicken): T193‑p
Characterization
 Methods used to characterize site in vivo:  phospho-antibody, western blotting
 Disease tissue studied:  lung cancer
 Relevant cell lines - cell types - tissues:  A549 (pulmonary)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
THC decrease
EGF increase
THC no change compared to control
THC EGF no effect upon treatment-induced increase
EGF increase
THC decrease
THC EGF inhibit treatment-induced increase
Associated Diseases
Diseases: Alterations: Comments:
non-small cell lung cancer

Y187-p - ERK2 (human) ▲
Orthologous residues
ERK2 (human): Y187‑p, ERK2 (mouse): Y185‑p, ERK2 (rat): Y185‑p, ERK2 (chicken): Y195‑p
Characterization
 Methods used to characterize site in vivo:  phospho-antibody, western blotting
 Disease tissue studied:  lung cancer
 Relevant cell lines - cell types - tissues:  A549 (pulmonary)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
THC decrease
EGF increase
THC no change compared to control
THC EGF no effect upon treatment-induced increase
EGF increase
THC decrease
THC EGF inhibit treatment-induced increase
Associated Diseases
Diseases: Alterations: Comments:
non-small cell lung cancer

Y397-p - FAK (human) ▲
Orthologous residues
FAK (human): Y397‑p, FAK iso2 (human): Y216‑p, FAK iso5 (human): Y397‑p, FAK (mouse): Y428‑p, FAK iso3 (mouse): Y397‑p, FAK iso4 (mouse): Y397‑p, FAK (rat): Y397‑p, FAK (chicken): Y397‑p, FAK iso5 (chicken): ‑
Characterization
 Methods used to characterize site in vivo:  phospho-antibody, western blotting
 Disease tissue studied:  lung cancer
 Relevant cell lines - cell types - tissues:  A549 (pulmonary)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
EGF increase
THC EGF augment treatment-induced increase
THC increase
THC decrease
Associated Diseases
Diseases: Alterations: Comments:
non-small cell lung cancer

T183-p - JNK2 (human) ▲
Orthologous residues
JNK2 (human): T183‑p, JNK2 iso2 (human): T183‑p, JNK2 iso3 (human): T183‑p, JNK2 (mouse): T183‑p, JNK2 (rat): T183‑p
Characterization
 Methods used to characterize site in vivo:  phospho-antibody, western blotting
 Disease tissue studied:  lung cancer
 Relevant cell lines - cell types - tissues:  A549 (pulmonary)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
EGF increase
THC no change compared to control
THC EGF inhibit treatment-induced increase
EGF increase
THC no change compared to control
THC EGF no effect upon treatment-induced increase
Associated Diseases
Diseases: Alterations: Comments:
non-small cell lung cancer

Y185-p - JNK2 (human) ▲
Orthologous residues
JNK2 (human): Y185‑p, JNK2 iso2 (human): Y185‑p, JNK2 iso3 (human): Y185‑p, JNK2 (mouse): Y185‑p, JNK2 (rat): Y185‑p
Characterization
 Methods used to characterize site in vivo:  phospho-antibody, western blotting
 Disease tissue studied:  lung cancer
 Relevant cell lines - cell types - tissues:  A549 (pulmonary)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
EGF increase
THC no change compared to control
THC EGF inhibit treatment-induced increase
EGF increase
THC no change compared to control
THC EGF no effect upon treatment-induced increase
Associated Diseases
Diseases: Alterations: Comments:
non-small cell lung cancer


Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.